Etanercept
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Etanercept: Hypermobility of coccyx
One-Sentence Summary
Etanercept is a TNF-blocking biologic, originally used for rheumatoid arthritis and related inflammatory arthritides such as psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis. Evidence for this specific prediction is weak, and the benefit-risk balance is unclear.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hypermobility of coccyx |
| TxGNN Prediction Score | 0.9963 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 8 of 8) |
| Number of DINs | 8 (marketed: 8) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Published reviews describe etanercept as a dimeric fusion protein of the p75 TNF receptor and the Fc portion of IgG1. It binds TNF-alpha and blocks its activity. Its efficacy in rheumatoid arthritis is established, and mechanistically it may be applicable to rheumatoid vasculitis.
Rheumatoid vasculitis is one of the most severe extra-articular manifestations of rheumatoid arthritis. It carries significant morbidity and mortality and usually needs aggressive treatment with corticosteroids and/or immunosuppressants. Because TNF-alpha is a central inflammatory driver in rheumatoid arthritis, blocking it is a plausible approach. A 2021 systematic review notes that biologic drugs have recently entered the treatment options for this condition.
There is also a significant counter-signal. Several case reports and cohort analyses describe cutaneous vasculitis, large-vessel vasculitis, “vasculitis-like events” and nephropathy occurring during etanercept or other anti-TNF therapy. TNF blockade can therefore paradoxically induce vasculitis in some patients, so the net benefit-risk for this use is uncertain.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients undergoing elective total shoulder arthroplasty. It compares how long medications are held before surgery and does not test etanercept for rheumatoid vasculitis, so it gives no direct evidence. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33058033 | 2021 | Systematic review | Clin Rheumatol | PRISMA-based review of biologic drugs in rheumatoid vasculitis, the most directly relevant item. The retrieved abstract does not state specific efficacy results. |
| 28391344 | 2017 | Review | Nephrol Dial Transplant | Discusses whether TNF-alpha blockade has a role in ANCA-associated vasculitis and glomerulonephritis. TNF-alpha is implicated in the pathophysiology, but efficacy in vasculitis is unproven. |
| 16624928 | 2006 | Review | J Am Soc Nephrol | Considers TNF-alpha as a therapeutic target in ANCA-associated vasculitis, drawing on other chronic inflammatory diseases. |
| 28123776 | 2017 | Cohort (BSRBR-RA) | RMD Open | Compares the risk of lupus-like and vasculitis-like events in TNF-inhibitor-treated versus conventional-DMARD-treated RA patients, with drug-specific risk. This is a safety signal. |
| 15853915 | 2005 | Review/Immunology | Scand J Immunol | Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Drug-induced vasculitis is rare. |
| 31632872 | 2019 | Case report/series | Cureus | Etanercept-associated nephropathy. Anti-TNF therapy in RA may lead to autoantibody formation. |
| 10955351 | 2000 | Case report | J Rheumatol | First reported case of leukocytoclastic vasculitis due to etanercept in severe RA. |
| 12209493 | 2002 | Case report | Arthritis Rheum | Accelerated nodulosis and vasculitis following etanercept therapy for RA. |
| 25544845 | 2014 | Case report | Case Rep Med | Large-vessel vasculitis occurring in an RA patient on anti-TNF therapy. |
| 19648728 | 2009 | Case report | Dermatology | Disseminated herpes zoster mimicking rheumatoid vasculitis in an RA patient on etanercept, which delayed diagnosis. |
The remaining publications retrieved are general reviews on anti-TNF safety, biosimilars, renal lesions, ocular complications and RA treatment. They do not address etanercept efficacy in rheumatoid vasculitis.
Canada Market Information
Eight valid single-ingredient authorizations are listed. Dosage form and approved-indication text were not available for these products.
| DIN | Product Name |
|---|---|
| 02274728 | ENBREL |
| 02530309 | RYMTI |
| 02462869 | ERELZI |
| 02462850 | ERELZI |
| 02462877 | ERELZI |
Three more authorizations are also valid: RYMTI (02530295) and BRENZYS (02455323, 02455331).
Safety Considerations
- Drug Interactions: The interaction screening returned 100 interacting drugs. The main ones are:
- Major: systemic and ophthalmic corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone), deferiprone, and radiopharmaceuticals or radio-immunotherapies (iobenguane I-131, ibritumomab tiuxetan, tositumomab).
- Moderate: metronidazole, tinidazole, rosuvastatin, simvastatin.
- Minor: zinc salts (sulfate, acetate, gluconate).
- Literature-reported safety signals: Reviews and case reports describe cutaneous vasculitis, large-vessel vasculitis, lupus-like events, nephropathy, and increased infection risk (including tuberculosis reactivation and herpes zoster) with anti-TNF therapy. These are especially relevant when the target condition is itself a vasculitis.
Conclusion and Next Steps
Decision: Hold
Rationale:
To proceed, the following is needed:
- Full-text review of the 2021 systematic review on biologics in rheumatoid vasculitis, to see what efficacy and safety data exist for etanercept specifically.
- Package insert warnings and contraindications for the Canadian products, to enable safety screening.
- Detailed mechanism-of-action data, to support a mechanistic link analysis.
- A benefit-risk assessment that addresses paradoxical TNF-inhibitor-induced vasculitis.
- Prospective or well-designed observational data in patients with rheumatoid vasculitis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.